The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2018 | IMPACT: expediting transplantation trials
The next 4 years are going to be exciting and productive for transplant research across a broad range of hematological malignancies. As explained here by David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, the new IMPACT platform will be a series of transplantation trials for patients with leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes and other hematological malignancies. Prof. Marks covers the trials planned for the first and second years of IMPACT, including PRO-DLI (NCT02856464), COSI and ALL-RIC.
